compounded semaglutide
Selected indexed studies
- Navigating compounded semaglutide: what health care providers need to know. (Am J Manag Care, 2025) [PMID:40966636]
- Weight loss and body composition after compounded semaglutide treatment in a real world setting. (Diabetes Obes Metab, 2025) [PMID:39776038]
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. (Ann Pharmacother, 2026) [PMID:41689811]
_Worker-drafted node — pending editorial review._
Connections
compounded semaglutide is a side effect of
Sources
- Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. (2025) pubmed
- GLP-1 agonists: A review for emergency clinicians. (2024) pubmed
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. (2026) pubmed
- Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. (2024) pubmed
- Navigating compounded semaglutide: what health care providers need to know. (2025) pubmed
- Weight loss and body composition after compounded semaglutide treatment in a real world setting. (2025) pubmed
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. (2026) pubmed
- Administration errors of compounded semaglutide reported to a poison control center-Case series. (2023) pubmed
- Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. (2025) pubmed
- Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend. (2025) pubmed